Xlife Sciences AG Stock Price

Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company’s project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also produces, researches, develops, and manufactures the chemical and active pharmaceutical ingredients for human and veterinary medicines; and offers clinical research organization services. In addition, the company builds a bridge between research/ development and healthcare markets, as well as support researchers and entrepreneurs in the positioning, structuring, development, and implementation of their ideas; and operates as an active ingredient manufacturer. Further, it focuses on identifying innovative biomarkers in the field of kidney diseases; the development of antibody-drug conjugates through a click chemistry approach and microfluidic screening of functional antibodies; and provides Neuromex, a screening instrument for the early-stage detection of neurological diseases. Xlife Sciences AG was founded in 2019 and is headquartered in Zurich, Switzerland.